Figure 1
VK2 selectively eliminates the MDS blastic population in vitro and in vivo. Upper panel: Mononuclear cells separated from the patient's peripheral blood were cultured in RPMI 1640 containing 10% fetal bovine serum in the presence or absence of 3 or 10 m MK4 for 72 h. Then the cells were analyzed by flow cytometry after staining with phycoerythrin-conjugated CD34 and fluorescein isothiocyanateconjugated CD33 monoclonal antibodies. Leukemic blast cells were separated as the CD34 ++ /CD33 dull+ fraction. Lower panel: After administration of MK4 (90 mg/day) for 6 weeks, the peripheral white blood cells were isolated by red blood cell lysis and analyzed as described above. The flow cytogram was compared with that obtained before treatment. Each number represents the percentage of blast cells in the whole gated area. 
COMMENTS ON A PUBLISHED PAPER
A more precise diagnosis of AML M0, a part of which exhibits a near-tetraploid karyotype TO THE EDITOR Villamor et al 1 described characteristics of nine cases of acute myeloblastic leukemia with minimal myeloid differentiation (AML M0). An abnormal karyotype was diagnosed only in two of six patients examined, ie in case No. 6 with 79-88 chromosomes (near-tetraploidy) in 20 metaphases and in case No. 8 with a complex karyotype.
These results extend our finding of near-tetraploid karyotypes in two patients with AML M0. . Both patients died of pancytopenia after induction treatments on the 24th and 52nd day of therapy, respectively. Recently we have shown 3 that at least six of 17 patients with near-tetraploid AML were classified as AML M0, often with erythroid and/or megakaryocytic dysplasia pointing to their origin in myeloid pluripotent progenitors. Near-tetraploid karyotype is easily morphologically recognized by the large blast size. 2, 3 Thus, AML M0 in a proportion of cases may be a subtype of near-tetraploid AML and in a further proportion a subtype of AML with a complex karyotype in the morphologic, immunologic, and cytogenetic (MIC) classification.
The establishment of the AML M0 diagnosis in patients with acute unclassified leukemias (AUL) with negativity of T and B lymphocytic markers and myeloperoxidase (MPO) was defined by the recommended positivity of 'myeloid' antigens CD13 and/or CD33 on unclassified leukemic blasts. 1, 4 However, the CD13 and CD33 antigens are not strictly specific for myeloid lineage 1, 4 and so as proof on unclassified blasts may not be sufficient for the correct diagnosis of AML M0. Even CD13 and/or CD33 antigens were found on blasts of neartetraploid acute lymphoblastic leukemias (ALL). 5 In two (Nos 3 and 4) of the nine cases of AML M0 presented by Villamor et al 1 the diagnosis was based only on the expression of one CD13 or CD33 antigen. However, the expression of two or more of the following myelomonocytic markers anti-MPO, CD13, CD33, CDw65, CD117, was required for the immunological diagnosis of AML. 6 Therefore a more complex diagnostic approach would be needed. Macrophage differentiation of leukemic blasts of AML in 4-day cultures with the 12-O-tetradecanoylphorbol-13-acetate (TPA) is a specific marker for the myeloid lineage because lymphoid blasts of ALL do not undergo macrophage differentiation.
2,7 Short-term cultivation of otherwise unclassified or unreliably classified leukemic blasts with TPA is the recommended diagnostic method to establish or confirm the diagnosis of AML M0 in such patients. This then facilitates the choice of an appropriate therapy.
